.Charles Baum, M.D., Ph.D., who oversaw Mirati Rehabs' $ 5.8 billion purchase to Bristol Myers Squibb in 2014, is taking the controls of younger biotech Terremoto Biosciences.Baum's "comprehensive expertise in drug development, as well as proven track record ahead of time high-impact medications, are going to be instrumental," outbound CEO Peter Thompson, M.D., said in a July 25 release. Thompson is going to retain his seat as board chairperson..Baum, an experienced physician-scientist, was the creator, head of state and chief executive officer of oncology-focused Mirati. Prior to that, he aided create cancer cells medicines at Pfizer and Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Right now, Baum is going to serve as chief executive officer at Terremoto, a company establishing little molecules to target disease-causing healthy proteins-- like those located in malignant growth tissues-- utilizing covalent connections. Existing treatments that make use of covalent bonds mainly target the amino acid cysteine. However, of the 20 amino acids that compose healthy proteins, cysteine is the minimum usual. Terremoto is actually instead targeting some of the essential amino acids, lysine, which is located in nearly all proteins.By targeting lysine and other amino acids, Terremoto intends to manage recently undruggable illness as well as develop first-in-class medications..The biotech, based in South San Francisco, brought up $75 thousand in collection A backing in 2022. A little bit of much more than a year later, the biotech greater than multiplied that amount in a $175 thousand set B.